twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical
company, today announced it has received a $225,030 Phase I Small
Business Innovation Research (SBIR) award from the National Cancer
Institute of the National Institutes of Health. The one-year award will
fund a program for twoXAR to use its AI-driven platform to identify and
validate new, first-in-class drug candidates for pancreatic ductal
adenocarcinoma (PDAC) that could improve patient survival outcomes.
PDAC is currently the fourth leading cause of cancer death in the United
States and is expected to be the second leading cause of cancer-related
death by 20301. PDAC patients have a median survival of less
than six months partly due to early metastasis, low immunogenicity, and
poor response to cytotoxic agents2. Few effective
treatments exist for PDAC, and the disease is known to become resistant
to current lines of therapy.
In this Phase I grant, twoXAR will use its computational platform to
identify drug candidates predicted to be efficacious for PDAC. The
efficacy of these compounds will be evaluated using in vitro and in
vivo preclinical assays, with the goal of developing and advancing a
lead candidate for clinical development. PDAC is one of many active
programs in twoXAR’s portfolio.
“We are honored to be awarded this SBIR grant and we appreciate the
support from the National Cancer Institute,” said Andrew A. Radin,
Co-Founder and CEO of twoXAR. “This program is an opportunity to
showcase twoXAR’s ability to rapidly and efficiently identify lead
compounds for the treatment of diseases with serious unmet medical need
such as PDAC. Our technology is unique in that it can leverage massive
amounts of existing real-world data to more holistically find better
treatments for patients.”
The content of this press release is solely the responsibility of
twoXAR, Inc. and does not necessarily represent the official views of
the National Institutes of Health. This press release discusses a
project that will be supported by National Cancer Institute of the
National Institutes of Health under award number R43 CA236164-01.
twoXAR is an artificial intelligence-driven biopharmaceutical company
that leverages its computational platform to identify promising drug
candidates, de-risk the opportunities through preclinical studies, and
progress drug product candidates into the clinic through industry
partnerships. Based in Mountain View, California, the twoXAR team
includes experts in drug discovery and development, biomedical
informatics, computational biology, data science and software
development. Investors in twoXAR include SoftBank Ventures, the
Andreessen Horowitz Bio Fund, OS Fund, CLI Ventures, and the
Stanford-StartX Fund. For more information, please visit www.twoXAR.com.
1 Chiaravalli M et al. Pancreatic ductal adenocarcinoma:
State-of-the-art 2017 and new therapeutic strategies. Cancer
Treatment Reviews. 2017;60:32-43.
2 Luchini C et al. Pancreatic Ductal Adenocarcinoma and Its
Variants. Surg Pathol Clin. 2016;9(4):547-60.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181128005137/en/